"The launch of generic competition to Axiron in the United...

"The launch of generic competition to Axiron in the United States will cause a material decline in Axiron’s net sales and the resulting royalties received by Acrux. At 2016 calendar year end there had not been a launch of a generic of Axiron." - so they also anticipate a "material decline" in royalties once the generics kick in! - explains cessation of dividend and their newfound concern at getting the pipeline going!!!!

anyone have an opinion on notes 3 & 4 to the accounts?. @stardestr0yer I think answer to your query regarding revenue may have been somewhat answered in note 3?.


wondering what the intangible asset amount on the balance sheet comprises and whether any increased amortisation charges should have been brought forward due to the axiron ruling. Maybe a shorter life now therefore increased amortisation cost and lower net assets? (but it may not work that way?).

half year report that doesn't disclose individual officeholder income bands.

anyhow as gypaetus has stated "always a good sign..." when the results are delivered on a Friday afternoon - isn't that what our beloved politicians do - bury what they don't want commented on late on a Friday afternoon - of course not even suggesting that that's the case here.